ULTRACET
LOE ApproachingNDAORALTABLET
Approved
Aug 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
3/8 — Basic
ULTRACET by Johnson & Johnson is clinical pharmacology the following information is based on studies of tramadol alone or acetaminophen alone, except where otherwise noted: pharmacodynamics ultracet contains tramadol and acetaminophen. First approved in 2001.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTRACET is an oral tablet small-molecule analgesic approved in 2001 by Johnson & Johnson. The product is a combination formulation designed for pain management. Specific mechanism of action and indicated conditions are not detailed in available data.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, likely characterized by declining headcount and cost-containment focus on the brand team.
Mechanism of Action
CLINICAL PHARMACOLOGY The following information is based on studies of tramadol alone or acetaminophen alone, except where otherwise noted: Pharmacodynamics ULTRACET contains tramadol and acetaminophen. Tramadol is a centrally acting synthetic opioid analgesic. Although its mode of action is not…
Worked on ULTRACET at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.